The global cardiac sarcoidosis landscape involves diagnosing, treating, and managing a rare heart inflammatory disease. It includes pharmaceuticals, diagnostics, and therapies addressing its unique challenges. With rising awareness and improved diagnostics, the sector undergoes shifts in supply and demand. Amidst evolving global healthcare, ongoing efforts to combat this condition offer hope to affected individuals and contribute to cardiovascular health advancements.
Access full Report @ https://www.databridgemarketresearch.com/reports/global-cardiac-sarcoidosis-market
Data Bridge Market Research analyses that the Global Cardiac Sarcoidosis Market, which was USD 22,669.05 million in 2022, is expected to reach USD 65,120.61 million by 2030, at a CAGR of 14.1% from 2023 to 2030. The expanding global aging population correlates with a heightened occurrence of cardiovascular diseases, notably cardiac sarcoidosis. This demographic shift amplifies the patient base, fueling market demand for diagnostic and therapeutic solutions to address the condition.
Key Findings of the Study
Corticosteroid treatment in cardiac sarcoidosis is expected to drive the market's growth rate
Corticosteroid treatment, a mainstay for cardiac sarcoidosis, may slow disease progression and improve survival. Despite not reducing ventricular arrhythmias, its mechanism involves rebalancing TH1/TH2, slowing inflammation and fibrosis. Prednisone doses, typically 60-80 mg/day initially, can be effective at 30 mg/day. Such therapeutic advancements fuel heightened demand for cardiac sarcoidosis diagnosis, emphasizing the crucial role of corticosteroids in improving patient outcomes and prognosis.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment (Diagnosis, Drugs), Drugs (Corticosteroids and Immunosuppressant Drugs), Inhibitors [Adalimumab, Infliximab and Others], Drugs Type (Branded, Generic), Route of Administration (Oral, Parenteral), End User (Hospitals, Specialty Clinics, Home Healthcare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Hikma Pharmaceuticals PLC (U.K.), Mylan N.V. (U.S.), Amneal Pharmaceuticals LLC. (U.S.), Mallinckrodt (U.K.), AbbVie Inc. (U.S.), Pfizer Inc. (U.S.), Relief Therapeutics (Switzerland), Sandoz International GmbH (Switzerland), Teva Pharmaceuticals USA, INC. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), sanofi-aventis U.S. LLC (U.S.), Zydus Pharmaceuticals, Inc. (U.S.), Fresenius Kabi USA (U.S.), Merck & Co., Inc. (U.S.)
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The global cardiac sarcoidosis market is segmented on the basis of treatment, drugs, inhibitors, drugs type, route of administration, end user and distribution channel.
- On the basis of treatment, the global cardiac sarcoidosis market is segmented into diagnosis, and drugs
- On the basis of drugs, the global cardiac sarcoidosis market is segmented into corticosteroids and immunosuppressant drugs
- On the basis of inhibitors, the global cardiac sarcoidosis market is segmented into adalimumab, infliximab and others
- On the basis of drug type, the global cardiac sarcoidosis market is segmented into branded, and generic
- On the basis of route of administration, the global cardiac sarcoidosis market is segmented into oral, and parenteral
- On the basis of end user, the global cardiac sarcoidosis market is segmented into hospitals, specialty clinics, home healthcare, and others
- On the basis of distribution channel, the global cardiac sarcoidosis market is segmented into hospital pharmacy, retail pharmacy, online pharmacy and others
Major Players
Data Bridge Market Research recognizes the following companies as the major global cardiac sarcoidosis market players in global cardiac sarcoidosis market are Hikma Pharmaceuticals PLC (U.K.), Mylan N.V. (U.S.), Amneal Pharmaceuticals LLC. (U.S.), Mallinckrodt (U.K.), AbbVie Inc. (U.S.), Pfizer Inc. (U.S.), Relief Therapeutics (Switzerland), Sandoz International GmbH (Switzerland), Teva Pharmaceuticals USA, INC. (U.S.)
Market Developments
- In April 2020, Mallinckrodt sponsored an awareness program launched by the American Lung Association (ALA) and the Foundation for Sarcoidosis Research (FSR) to empower sarcoidosis patients to fight against such a chronic disease and follow some measures to protect themselves from cardiac sarcoidosis. The launch of this awareness campaign aided the company in raising its public profile
- In July 2019, Hikma Pharmaceuticals PLC and Civica entered a five-year agreement to reduce the generic drug shortage in the United States. Most drugs used to treat cardiac sarcoidosis, including methotrexate, are available as generic drugs. This agreement enabled the company to maintain a continuous drug supply, allowing it to invest significantly in expanding its manufacturing capabilities
Regional Analysis
Geographically, the countries covered in the global cardiac sarcoidosis market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
As per Data Bridge Market Research analysis:
North America is the dominant region in the global cardiac sarcoidosis market during the forecast period 2023-2030
North America dominates the global cardiac sarcoidosis market, propelled by the widespread adoption of effective cardiac sarcoidosis drugs. The region's proactive use of these medications contributes significantly to the market's dominance, reflecting a robust healthcare infrastructure and a focus on advanced therapeutic interventions. As the demand for cardiac sarcoidosis drugs grows, North America plays a pivotal role in shaping and driving market dynamics.
Asia-Pacific is estimated to be the fastest-growing region in global cardiac sarcoidosis market during the forecast period 2023-2030
Asia-Pacific is expected to dominate the global cardiac sarcoidosis market, experiencing the highest growth from 2023 to 2030. This surge is attributed to the increasing incidence of cardiac sarcoidosis and notable advancements in technology within the region. The expanding pharmaceutical landscape and ongoing technological innovations position Asia-Pacific as a key contributor to the market's growth, reflecting the region's commitment to addressing the challenges posed by cardiac sarcoidosis through progressive healthcare measures.
For more detailed information about the global cardiac sarcoidosis market report, click here – https://www.databridgemarketresearch.com/reports/global-cardiac-sarcoidosis-market
